Tag: XTLY

EBIO and XTLY may have bullish sentiments

EBIO – Eleven Biotherapeutics, Inc, a clinical-stage biotech company, hit the bottom after announcing that its investigational eye drop failed as a cure for allergic conjunctivitis.

EBIO – Eleven Biotherepeutics, Inc
Fundamentals Previously closed at 0.31
Day’s high 0.31
Day’s low 0.27
P/E ratio NA
EPS -1.71

 

Analyst opinion The recent stock sell-off’s seem to have hit the biotech company really hard, with EBIO hitting a new low, losing more than 90% in value as compared to last year. The failed- experimental eye-drop “isunakinra”, being the biggest reason for the price drop. However, just a week ago, the market cap of EBIO was as low as $5.3 million, which is way low compared to its cash balance reported at the end of Q3 last year which amounts to $46 million
Sentiments Though EPS is negative, we can see that the EPS has improved compared to prior year. EBIO has good fundamentals with a P/S ratio of 7.04, a P/B ratio of 0.20, a P/C ratio of 0.12 and a Quick ratio of 6.20.
91% analysts have a buy opinion for the stock.
Social pulse The social media pulse is 35% lower than normal.

Continue Reading…